Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER_GOV × tislelizumab × Dermatologic × Clear all

Phase

Status

Sponsor Class

INDUSTRY 5 OTHER 4 OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 15 Thoracic 4 Head & Neck 2 Dermatologic 1

Conditions

Interventions

Nivolumab 5 Interleukin-2 4 pembrolizumab 3 Melphalan 3 Ipilimumab 3 apatinib 2 tremelimumab 1 tislelizumab 1 fludarabine 1 entinostat 1 encorafenib 1 camrelizumab 1 binimetinib 1 Tramadol 1 Surgical Procedures, Operative 1 Physical Examination 1 Mohs Surgery 1 Microscopy, Confocal 1 Methotrexate 1 Metastasectomy 1 Immunotherapy 1 Ibuprofen 1 FMT protocol 1 Dermoscopy 1 Cyclophosphamide 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04924413 2024-07-03

L-TIL Plus Tislelizumab as First-line Treatment in Advanced Malignant Melanoma

Henan Cancer Hospital

Phase 2 Terminated

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡